References
- Manaloto R. M., Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25: 121–3
- Chan H. H. Effective and safe use of lasers, light sources, and radiofrequency devices in the clinical management of Asian patients with selected dermatoses. Lasers Surg Med 2005; 37: 179–85
- Goldman M. P. The use of hydroquinone with facial laser resurfacing. J Cutan Laser Ther 2000; 2: 73–7
- Munnoch D. A., Gorst C. M., Hancock K. Post laser hyperpigmentation and occupational ultraviolet radiation exposure. Br J Plast Surg 2000; 53: 259–61
- Bhatt N., Alster T. S. Laser surgery in dark skin. Dermatol Surg 2008; 34: 184–94
- Espinal‐Perez L., Moncada B., Castanedo‐Cazares P. A double‐blind randomized trial of 5% ascorbic acid vs 4% hydroquinone in melasma. Int J Dermatol 2004; 43: 604–7
- Ochiai Y., Kaburagi S., Obayashi K., Ujiie N., Hashimoto S., Okano Y., et al. A new lipophilic pro‐vitamin C, tetra‐isopalmitoyl ascorbic acid (VC‐IP), prevents UV‐induced skin pigmentation through its anti‐oxidative properties. J Dermatol Sci 2006; 44: 37–44
- Huh C. H., Seo K. I., Park J. Y., Lim J. G., Eun H. C., Park K. C. A randomized, double‐blind, placebo‐controlled trial of vitamin C iontophoresis in melasma. Dermatology 2003; 206: 306–20
- Padayatty S. J., Sun H., Wang Y., Riordan H. D., Hewitt S. M., Katz A., et al. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 2004; 140: 533–7
- Massey L. K., Liebman M., Kynast‐Gales S. A. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005; 35: 1673–7